Webinar: Avoid The Valley of Death – Increase Confidence in Translational Research Using Biosimulation – September 12th

Only a third of preclinical programs make it to Phase 1 trials. Honing translational research is key to reducing the substantial financial risk associated with drug development. A new tool to help narrow the focus of preclinical programs is physiologically-based pharmacokinetic modeling (PBPK) modeling and simulation. Correct implementation can help predict human doses, find prime targets, and identify interactions.

According to Fierce Pharma, “Hannah has more than 20 years of experience in global pharmaceutical organizations, with a particularly strong background in PBPK and PKPD modelling.  She has over 60 publications in PBPK/PKPD modelling and other DMPK related topics, and considerable experience influencing drug research and development programs through modelling and simulation.  Previously, Dr. Jones was at Pfizer for more than 13 years, most recently as Executive Director with global oversight of all preclinical large molecule translational science activities, including responsibility for modelling and simulation as well as biomarker and biomeasure support.”

To register, click here.

(Source: Fierce Pharma, September 7^th, 2022)